Vaccination with recombinant actin from scab mites and evaluation of its protective efficacy againstPsoroptes cuniculiinfection
W. ZHENG, Q. TANG, R. ZHANG, Q. JISE, Y. REN, X. NONG, X. WU, X. GU, S. WANG, X. PENG, S. LAI& G. YANG
Abstract
The mitePsoroptescuniculiis globally widespread and has a serious impact on commercial rabbit breeding. Current treatment methods are based on chemotherapy. Because of the disadvantages of these methods, alternative measures are required, andvaccinationis one of the most promising strategies. Here, we cloned and expressed therecombinantP.cuniculiactingene (rPc-act). Antiserum levelsagainstrPc-act in rabbits were used to locateactindistribution in mite sections. Challenge trials were carried out to evaluate the immunity protection of rPc-act in rabbits, with antibody levels determined by ELISA. Sequence analysis of this gene fragment showed 89·26% and 84·91% identity to Sarcoptes scabiei and Mayetiola destructor sequences, respectively. Immunohistochemistry showed rPc-act to locate widely throughout themites, especially in feet and muscle tissues.RecombinantP.cuniculiactinwith QuliA adjuvant was used to immunize six rabbits. Each animal was challenge-infested with 25-50 adultmites. Although IgE levels showed no significant difference to controls, IgG levels were significantly higher, and clinical development showed no significantly different severity of lesions in vaccinated rabbits than in the controls. This study showed that rPc-act is a muscular isotypeactinand has no clinicalprotectiveefficacyagainstP.cuniculi.
Copyright© 2012 Blackwell Publishing Ltd.
Parasite Immunol.2013 Feb;35(2):91-8. doi: 10.1111/pim.12015.
Read full text:http://onlinelibrary.wiley.com/doi/10.1111/pim.12015/abstract
